Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib in Relapsed or Refractory AML
NCT02014558Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2013
- Primary completion
- Aug 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 2 trial of gilteritinib in acute myeloid leukemia (AML), sponsored by Astellas Pharma. Started Oct 2013; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02014558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014558.